| Ytd | 4.14% | |
| 1y | 63.49% |
| Open | 36.18 | Prev Close | 35.99 | Low | 35.35 | High | 36.18 | Mkt Cap | 3.42B |
| Vol | 4.73K | Avg Vol | 1.13M | EPS | -1.60 | P/E | -22.49 | Forward P/E | 4.65 |
| Beta | -0.09 | Short Ratio | 6.53 | Inst. Own | 101.90% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-05 | 50-d Avg | 32.30 | 200-d Avg | 32.38 | 1yr Est | 52.29 |
IDEAYA Presentations:2092P (Poster Presentation); Neoadjuvant Darovasertib in Primary Uveal Melanoma
SOUTH SAN FRANCISCO, Calif., July 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA),
RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform
Truist Securities analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and
U.S. stock futures higher, Nasdaq up 200 points. Mission Produce (NASDAQ: AVO) shares down on weak e
GSK to acquire Nuvalent for $10.6 billion, shares rise 38.2%. Other gainers include CCTG, CHAI, RGNT
U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt ro
Editor’s note: The future prices of benchmark tracking ETFs and pre-market prices of stocks have bee
IDEAYA Biosciences shares (NASDAQ: IDYA) jumped 18% in pre-market trading after announcing topline
During Thursday, 849 stocks hit new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.